Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J G BAXTER

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Neuroimaging Clinics of North America|August 3, 2011
Congenital midface abnormalitiesDaniel J G Baxter, Manohar Shroff
Journal of the American Chemical Society|March 19, 2010
Neovitamin AC D ROBESON, J G BAXTER
Seminars in Ultrasound, CT, and MR|November 24, 2011
Developmental maxillofacial anomaliesDaniel J G Baxter, Manohar M Shroff
Renal Failure|October 12, 1999
Oral phosphate binders: phosphate binding capacity of iron (III) hydroxide complexes containing saccharides and their effect on the urinary excretion of calcium and phosphate in ratsT Yamaguchi, J G Baxter, N Maebashi, et al.
Internationale Zeitschrift Fur Vitaminforschung. International Journal of Vitamin Research. Journal International De Vitaminologie|February 19, 2014
Prevention by d,a-tocopherol of increased capillary fragility in rats following irradiationS R AMES, J G BAXTER, J Q GRIFFITH
Journal of Pharmaceutical Sciences|May 1, 1986
Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogsJ G Baxter, C Brass, J J Schentag, et al.
Clinical Pharmacokinetics|November 1, 1986
Free drug concentration monitoring in clinical practice. Rationale and current statusC K Svensson, M N Woodruff, J G Baxter, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 1998
Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteersC Prakash, D Cui, J G Baxter, et al.
Annals of Surgery|January 1, 1985
Clinical risk factors for prolonged PT/PTT in abdominal sepsis patients treated with moxalactam or tobramycin plus clindamycinJ G Baxter, D A Marble, L R Whitfield, et al.
Psychopharmacology|January 1, 1992
Pharmacokinetic and metabolic aspects of the moclobemide-food interactionA F Cole, J G Baxter, B J Jackson, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Neuroimaging Clinics of North America|August 3, 2011
Congenital midface abnormalitiesDaniel J G Baxter, Manohar Shroff
Journal of the American Chemical Society|March 19, 2010
Neovitamin AC D ROBESON, J G BAXTER
Seminars in Ultrasound, CT, and MR|November 24, 2011
Developmental maxillofacial anomaliesDaniel J G Baxter, Manohar M Shroff
Renal Failure|October 12, 1999
Oral phosphate binders: phosphate binding capacity of iron (III) hydroxide complexes containing saccharides and their effect on the urinary excretion of calcium and phosphate in ratsT Yamaguchi, J G Baxter, N Maebashi, et al.
Internationale Zeitschrift Fur Vitaminforschung. International Journal of Vitamin Research. Journal International De Vitaminologie|February 19, 2014
Prevention by d,a-tocopherol of increased capillary fragility in rats following irradiationS R AMES, J G BAXTER, J Q GRIFFITH
Journal of Pharmaceutical Sciences|May 1, 1986
Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogsJ G Baxter, C Brass, J J Schentag, et al.
Clinical Pharmacokinetics|November 1, 1986
Free drug concentration monitoring in clinical practice. Rationale and current statusC K Svensson, M N Woodruff, J G Baxter, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 1998
Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteersC Prakash, D Cui, J G Baxter, et al.
Annals of Surgery|January 1, 1985
Clinical risk factors for prolonged PT/PTT in abdominal sepsis patients treated with moxalactam or tobramycin plus clindamycinJ G Baxter, D A Marble, L R Whitfield, et al.
Psychopharmacology|January 1, 1992
Pharmacokinetic and metabolic aspects of the moclobemide-food interactionA F Cole, J G Baxter, B J Jackson, et al.
Pageof 2